-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shi Si Pharmaceutical Group Named “Best Small- and Mid-Cap Company”
Category:
Time：2022-12-20
On December 19, the 7th Zhitong Finance Capital Markets Annual Conference and the Golden Hong Kong Stocks Awards Ceremony, jointly hosted by Zhitong Finance, China Galaxy Securities, and Tonghuashun Finance, was held with great success in Hangzhou. At the awards ceremony, Shisi Pharmaceutical Group was honored with the “Best Small- and Mid-Cap Company” award.
On December 19, the 7th Zhitong Finance Capital Markets Annual Conference and the Golden Hong Kong Stocks Awards Ceremony, jointly hosted by Zhitong Finance, China Galaxy Securities, and Tonghuashun Finance, was held with great success in Hangzhou. At the awards ceremony, Shisi Pharmaceutical Group was honored with the “Best Small- and Mid-Cap Company” award.
It is reported that “Golden Hong Kong Stocks,” now in its seventh year, has risen to become the premier annual event celebrating Hong Kong stocks, emerging as the world’s most authoritative ranking of Hong Kong-listed companies and serving as a key indicator of the year’s most promising investment opportunities and growth potential in Hong Kong stocks. Moreover, it has evolved into a vibrant forum for intellectual exchange among China’s business leaders, earning widespread recognition from investors worldwide. The “Best Small- and Mid-Cap Company” award is designed to honor Hong Kong-listed companies in the small- and mid-cap segment whose business strategies align with growth expectations, currently demonstrate strong operational performance, and boast significant growth potential.
As a major backbone enterprise in China’s pharmaceutical industry, in recent years, Shiyao Group has leveraged its own strengths and focused on the core theme of transformation, upgrading, quality enhancement, and efficiency improvement. Guided by innovative development, the group has actively implemented a “four-wheel drive” synergy strategy encompassing generic drugs, active pharmaceutical ingredients, innovative drugs, and pharmaceutical packaging materials. By significantly increasing investment in innovation and relying on high-level innovation research platforms—such as the national-level enterprise technology center and the national-local joint engineering laboratory that integrate industry, academia, research, and application—the group has established a comprehensive, scientific, and well-defined path for technological innovation and product development. It continues to strategically position itself and exert strong efforts in areas such as first-to-market generic drugs, innovative drugs, specialty APIs, pharmaceutical packaging materials, and advanced complex formulations, thereby continuously empowering the company’s high-quality development. Since the beginning of this year, Shiyao Group has ranked among the top pharmaceutical companies nationwide in terms of both the efficiency and volume of its specialty generic drug R&D, and has made positive progress in innovative drug research.
Meanwhile, Shiyao Group has been strategically aligning its industrial chain with the innovation chain, enhancing its value chain through the industrial chain, and accelerating the development of new, iteratively improved products with high added value and promising market prospects. As a result, its sales in both domestic and international markets have maintained a steady growth trend. In the first three quarters of this year, Shiyao Group achieved rapid revenue growth, establishing itself as a key driver of innovation and development in China’s pharmaceutical industry and attracting widespread attention from the capital market.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license